Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: A Clinical and Correlative Study

Trial Profile

Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: A Clinical and Correlative Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 07 Aug 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2019.
    • 07 Aug 2017 Status changed from active, no longer recruiting to recruiting.
    • 07 Oct 2016 Planned End Date changed from 1 Sep 2018 to 1 Sep 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top